-
EDAP Reports First Quarter 2024 Financial Results
Source: Nasdaq GlobeNewswire / 16 May 2024 07:00:00 America/Chicago
- Strong Q1 2024 U.S. Focal One® HIFU procedure growth of +92% year-over-year
- Q1 2024 HIFU revenue of EUR 5.8 million ($6.3 million USD), an increase of 10.2% over Q1 2023
- Q1 2024 total revenue of EUR 14.9 million ($16.1 million USD) increased 0.8% over Q1 2023
- Company to host conference call and webcast today, May 16th, at 8:30 a.m. EDT
LYON, France, May 16, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today unaudited financial results for the first quarter of 2024.
“We are off to a strong start in 2024 driven by seven Focal One system placements in the quarter of 2024 and strong year over year procedure growth, reflecting the increasing acceptance of robotic HIFU for the management of prostate cancer,” said Ryan Rhodes, Chief Executive Officer of EDAP TMS. “Important to note, the final results from the HIFI study, which is the single largest comparative study ever conducted evaluating robotic HIFU versus radical prostatectomy, were just presented at the119th Annual Meeting of the America Urology Association, held in San Antonio, Texas. The final results from the study were presented during the main plenary session of the AUA, which focused exclusively on evolving practices and changing treatment paradigms in urology. We believe the results from the HIFI Study clearly demonstrate that Focal One robotic HIFU delivers effective oncologic control as compared to surgery, but with the added potential benefit for improved functional outcomes with respect to maintaining both erectile function and urinary continence. Based on these definitive results, we expect to see both growing and continued adoption of our Focal One robotic HIFU technology in the management of localized prostate cancer.
“EDAP continues to make strategic investments to grow HIFU applications beyond prostate health. Last quarter, we received Breakthrough Device designation from the FDA for the application of Focal One robotic HIFU for treatment of deep infiltrating rectal endometriosis. As noted, our Phase 3 study completed patient enrollment in January, and we expect topline results from this study in the second half of 2024. Endometriosis represents a significant unmet medical need in women’s health, and we believe Focal One has the opportunity to become an important new treatment alternative to address this painful and debilitating condition which impacts thousands of women each year.
“Looking ahead in 2024, we believe Focal One will become an essential component to the urology suite, as an increasing number of patients seek out effective, less invasive treatment options to manage their prostate cancer. Our Focal One pipeline remains strong, and we continue to see broad acceptance of Focal One amongst leading academic and community medical practices. We also continue to see strong engagement across our regional capital and clinical sales teams, as they build world-class robotic HIFU treatment programs with the goal of helping more urology practices remain at the forefront of prostate cancer management.”
Business Update
- On May 6, 2024, the Company announced that final results from a large, prospective, multicenter, non-inferiority study, the HIFI Study, comparing Focal One® high intensity focused ultrasound (HIFU) versus radical prostatectomy (RP) were presented at the 119th American Urological Association Annual Meeting (AUA 2024), which took place from May 3-6, 2024, in San Antonio, Texas, USA. Professor Pascal Rischmann of Rangueil University Hospital in Toulouse, France, and lead investigator of the HIFI Study, highlighted the final results from the study during an oral presentation at the AUA plenary session, “Paradigm-shifting, Practice-changing Clinical Trials in Urology”.
- On February 1, 2024, the Company announced that it completed enrollment for its Phase 3 study (Endo-HIFU-R2) evaluating Focal One High-Intensity Focused Ultrasound (HIFU) therapy for the treatment of deep infiltrating rectal endometriosis. Results from the Phase 3 study are expected in the second half of 2024.
- On January 2, 2024, the Company announced the appointments of Ken Mobeck as its Chief Financial Officer of EDAP worldwide, and Francois Dietsch as Global Chief Accounting Officer. Both appointments became effective as of January 1, 2024.
Clinical Pipeline Update
Endometriosis Program
- On March 4, 2024, the Company announced that it received Breakthrough Device designation by the US Food and Drug Administration (FDA) for the treatment of deep infiltrating endometriosis (DIE). FDA’s Breakthrough Device designation is granted to products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. This unique program is intended to provide patients and health care providers with timely access to medical devices by speeding up development, assessment, and review.
- On February 1, 2024, EDAP announced completion of enrollment in the Phase 3 double blinded, randomized controlled trial evaluating Focal One HIFU for the treatment of deep infiltrating rectal endometriosis. Results from the study are expected in the second half of 2024.
Upcoming Meetings and Events
- Jefferies Global Healthcare Conference, June 5-6, 2024, in New York City
First Quarter 2024 Results
Total revenue for the first quarter of 2024 was EUR 14.9 million (USD 16.1 million), an increase of 0.8% as compared to total revenue of EUR 14.8 million (USD 15.9 million) for the same period in 2023.
Total revenue in the HIFU business for the first quarter of 2024 was EUR 5.8 million (USD 6.3 million), as compared to EUR 5.3 million (USD 5.7 million) for the first quarter of 2023. The Company recorded a 55.7% year-over-year growth in disposables revenues, reflecting strong procedure growth. During the quarter, the Company placed 7 Focal One systems, which included five capital sales, versus 7 Focal One placements in the first quarter of 2023.
Total revenue in the LITHO business for the first quarter of 2024 was EUR 2.3 million (USD 2.8 million), as compared to EUR 2.8 million (USD 3.0 million) for the first quarter of 2023. The decrease in LITHO revenue was driven by 2 lithotripsy units sold in the first quarter of 2024 as compared to 4 units sold in the first quarter of 2023.
Total revenue in the Distribution business for the first quarter of 2024 was EUR 6.9 million (USD 7.4 million), as compared to EUR 6.8 million (USD 7.3 million) for the first quarter of 2023. The increase in Distribution revenue was driven primarily by 11 ExactVu units sold during the first quarter of 2024 as compared to 8 units sold during the first quarter of 2023.
Gross profit for the first quarter of 2024 was EUR 6.4 million (USD 6.9 million), compared to EUR 6.0 million (USD 6.5 million) for the year-ago period. Gross profit margin on net sales was 42.8% in the first quarter of 2024, compared to 40.8% in the year-ago period. The increase in gross profit margin year-over-year was primarily due to the higher level of treatment driven revenues which generates higher gross margin.
Operating expenses were 11.2 million euros (12.1 million in US Dollars) for the first quarter, compared to 12.6 million euros (13.6 million in US Dollars) for the same period in 2023. The decrease in operating expenses was due to the recording in Q1 2023 of a one-time, non-recurring employee compensation expense. The impact from this one-time expense in Q1 2023 was offset by the continued investment in the Company’s U.S. commercial operations.
Operating loss for the first quarter of 2024 was EUR 4.8 million (USD 5.2 million), compared to an operating loss of EUR 6.6 million (USD 7.1 million) in the first quarter of 2023.
Net loss for the first quarter of 2024 was EUR 4.5 million (USD 4.9 million), or EUR (0.12) per diluted share, as compared to net loss of EUR 7.5 million (USD 8.1 million), or EUR (0.20) per diluted share in the year-ago period.
Conference Call
A conference call and webcast to discuss the first quarter 2024 financial results will be hosted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration.
Date: Thursday, May 16th @ 8:30am Eastern Time
Domestic: 1-877-451-6152
International: 1-201-389-0879
Passcode (Conf ID): 13745791
Call me™: https://callme.viavid.com/viavid/?callme=true&passcode=13712293&h=true&info=company-email&r=true&B=6- Participants can use Guest dial-in #s above and be answered by an operator OR click the Call me™ link for instant telephone access to the event.
- Call me™ link will be made active 15 minutes prior to scheduled start time.
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1665376&tp_key=00daa24457
About EDAP TMS SA
A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, us.hifu-prostate.com and www.focalone.com.Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of applicable federal securities laws, including Section 27A of the U.S. Securities Act of 1933 (the “Securities Act”) or Section 21E of the U.S. Securities Exchange Act of 1934, which may be identified by words such as “believe,” “can,” “contemplate,” “could,” “plan,” “intend,” “is designed to,” “may,” “might,” “potential,” “objective,” “target,” “project,” “predict,” “forecast,” “ambition,” “guideline,” “should,” “will,” “estimate,” “expect” and “anticipate,” or the negative of these and similar expressions, which reflect our views about future events and financial performance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy and distribution divisions, as well as risks associated with the current worldwide inflationary environment, the uncertain worldwide economic, political and financial environment, geopolitical instability, climate change and pandemics like the COVID 19 pandemic, or other public health crises, and their related impact on our business operations, including their impacts across our businesses or demand for our devices and services.Other factors that may cause such a difference may also include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.
Forward-looking statements speak only as of the date they are made. Other than required by law, we do not undertake any obligation to update them in light of new information or future developments. These forward-looking statements are based upon information, assumptions and estimates available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete.
Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.comInvestor Contact
John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
jfraunces@lifesciadvisors.comEDAP TMS S.A.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands of Euros and U.S. Dollars, except per share data)Three Months Ended: Three Months Ended: March 31, March 31, March 31, March 31, 2024 2023 2024 2023 Euros Euros $US $US Sales of medical equipment 9,967 10,319 10,782 11,121 Net Sales of RPP and Leases 1,775 1,579 1,921 1,701 Sales of spare parts, supplies and Services 3,165 2,897 3,424 3,123 TOTAL NET SALES 14,908 14,795 16,127 15,945 Other revenues — — — — TOTAL REVENUES 14,908 14,795 16,127 15,945 Cost of sales (8,523) (8,764) (9,220) (9,445) GROSS PROFIT 6,385 6,032 6,907 6,500 Research & development expenses (2,069) (1,458) (2,238) (1,571) S, G & A expenses (9,132) (11,130) (9,879) (11,995) Total operating expenses (11,201) (12,588) (12,117) (13,566) OPERATING PROFIT (LOSS) (4,816) (6,556) (5,210) (7,066) Interest (expense) income, net 145 256 157 276 Currency exchange gains (loss), net 236 (1,145) 255 (1,234) INCOME (LOSS) BEFORE TAXES AND MINORITY INTEREST (4,435) (7,445) (4,798) (8,024) Income tax (expense) credit (111) (46) (120) (49) NET INCOME (LOSS) (4,546) (7,491) (4,918) (8,073) Earning per share – Basic (0.12) (0.20) (0.13) (0.22) Average number of shares used in computation of EPS 36,996,722 36,922,286 36,996,722 36,922,286 Earning per share – Diluted (0.12) (0.20) (0.13) (0.22) Average number of shares used in computation of EPS for positive net income 36,996,722 36,922,286 36,996,722 36,922,286 NOTE: Translated for convenience of the reader to U.S. dollars at the 2024 average three months’ noon buying rate of 1 Euro = 1.0818 USD, and 2023 average three months noon buying rate of 1 Euro = 1.0777 USD
EDAP TMS S.A.
UNAUDITED CONSOLIDATED BALANCE SHEETS HIGHLIGHTS
(Amounts in thousands of Euros and U.S. Dollars)March 31, December 31, March 31, December 31, 2024 2023 2024 2023 Euros Euros $US $US Cash, cash equivalents and short-term treasury investments 38,441 43,471 41,482 48,087 Account receivables, net 17,009 19,238 18,355 21,281 Inventory 17,451 15,112 18,831 16,717 Other current assets 1,189 659 1,283 729 TOTAL CURRENT ASSETS 74,091 78,480 79,951 86,814 Property, plant and equipment, net 10,106 8,193 10,906 9,063 Goodwill 2,412 2,412 2,603 2,668 Other non-current assets 2,469 2,464 2,665 2,725 TOTAL ASSETS 89,078 91,548 96,124 101,270 Accounts payable & other accrued liabilities 18,659 18,435 20,135 20,392 Deferred revenues, current portion 4,123 4,049 4,449 4,479 Short term borrowing 2,719 2,466 2,934 2,728 Other current liabilities 2,791 2,646 3,012 2,927 TOTAL CURRENT LIABILITIES 28,293 27,596 30,531 30,526 Obligations under operating and finance leases non-current 2,498 1,315 2,696 1,454 Long term debt, non-current 1,621 1,997 1,749 2,209 Deferred revenues, non-current 598 643 645 712 Other long term liabilities 3,081 3,075 3,325 3,402 TOTAL LIABILITIES 36,091 34,626 38,946 38,304 TOTAL SHAREHOLDERS’EQUITY 52,987 56,922 57,178 62,966 TOTAL LIABILITIES & SHAREHOLDERS’ EQUITY 89,078 91,548 96,124 101,270 NOTE: Translated for convenience of the reader to U.S. dollars at the noon buying rate of 1 Euro = 1.0791 USD, on March 31, 2024 and at the noon buying rate of 1 Euro = 1.1062 USD, on December 31, 2023.
EDAP TMS S.A.
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands of Euros)Three Months Ended Twelve Months Ended Three Months Ended Twelve Months Ended March 31, December 31, March 31, December 31, 2024 2023 2024 2023 (Euros) (Euros) ($US) ($US) NET INCOME (LOSS) (4,546) (21,178) (4,918) (22,930) Adjustments to reconcile net income (loss) to net cash generated by (used in) operating activities(1) 1,340 9,403 1,450 10,181 OPERATING CASH FLOW (3,206) (11,775) (3,468) (12,749) Increase/Decrease in operating assets and liabilities (544) (2,903) (589) (3,144) NET CASH GENERATED BY (USED IN) OPERATING ACTIVITIES (3,750) (14,678) (4,057) (15,892) Short term investments — (0) — (0) Additions to capitalized assets produced by the company and other capital expenditures (1,098) (4,344) (1,188) (4,704) NET CASH GENERATED BY (USED IN) INVESTING ACTIVITIES (1,098) (4,344) (1,188) (4,704) NET CASH GENERATED BY (USED IN) FINANCING ACTIVITIES (167) (911) (181) (986) NET EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS (13) 268 (1,179) 2,130 NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (5,029) (19,666) (6,605) (19,452) (1) including share based compensation expenses for 692 thousand of Euros for the three months ended March 31, 2024 and 6,865 thousand of Euros for the full year ended December 31, 2023.
NOTE: Translated for convenience of the reader to U.S. dollars at the 2024 average three months’ noon buying rate of 1 Euro = 1.0818 USD, and 2023 average twelve months noon buying rate of 1 Euro = 1.0827 USD
EDAP TMS S.A.
UNAUDITED CONDENSED STATEMENTS OF OPERATIONS BY DIVISION
three months ended March 31, 2024
(Amounts in thousands of Euros)HIFU ESWL Distribution Reconciling Total After Division Division Division Items Consolidation Sales of goods 3,708 832 5,427 — 9,967 Sales of RPPs & Leases 1,458 262 55 — 1,775 Sales of spare parts & services 618 1,177 1,370 — 3,165 TOTAL NET SALES 5,784 2,271 6,852 — 14,908 Other revenues — — — — — TOTAL REVENUES 5,784 2,271 6,852 — 14,908 GROSS PROFIT (% of Net Sales) 3,003 51.9 % 949 41.8 % 2,433 35.5 % — 6,385 42.8 % Research & Development (1,752) (125) (192) — (2,069) Total SG&A plus depreciation (5,195) (439) (2,502) (996) (9,132) OPERATING PROFIT (LOSS) (3,943) 384 (261) (996) (4,816) Attachment
